Emu Oil and Saireito in combination reduce tumour development and clinical indicators of disease in a mouse model of colitis-associated colorectal cancer

Emu Oil (EO) previously demonstrated therapeutic potential in a mouse model of colitis-associated CRC (CA-CRC). Saireito, traditional Japanese medicine, has not been investigated CA-CRC. To determine whether EO and Saireito could be an azoxymethane (AOM)/dextran sulphate sodium (DSS) Female C57BL/6 mice were assigned to groups (n = 10/group); 1) saline control, 2) saline+Saireito, 3) saline+EO, 4) saline+EO/Saireito, 5) AOM/DSS 6) AOM/DSS+Saireito, 7) AOM/DSS+EO 8) AOM/DSS+EO/Saireito. Mice intraperitoneally injected with or AOM (7.4 mg/kg) on day 0 underwent three DSS/water cycles (2%w/v DSS for 7 days, 14 days water). orally-gavaged either water (80 µL), µL) EO/Saireito (160 µL; 80 µL + Saireito) thrice weekly. Daily bodyweight disease activity index (DAI) recorded colonoscopies performed 20, 41 62. euthanized 63. p < 0.05 was considered statistically significant. induced significant loss throughout the trial (max −36%), which attenuated by +7%), +5%) +14%; 0.05). increased DAI compared controls (p 0.05), reduced All treatments colonoscopically-assessed colitis severity (days 20 41; further decreased alone (day 20; Finally, resulted fewer colonic tumours Combined tumour development mice, suggesting